Gelonghui, January 24, 丨 Chenghui Pharmaceutical (603811.SH) announced. Recently, the Office of the National High-tech Enterprise Certification and Management Leading Group issued the “Notice on Filing the Second Batch of High-tech Enterprises Certified by Fujian Accreditation Agencies in 2023". The company's holding subsidiary Fujian Huakang Pharmaceutical Co., Ltd. (hereinafter referred to as “Huakang Pharmaceutical”) was included in the second batch of high-tech enterprise filing list certified and reported by the Fujian Provincial Accreditation Agency in 2023. Certificate number: GR202335003219, date of issue: December 28, 2023. Validity period: 3 years. The first certification of Huakang Pharmaceutical's high-tech enterprise is a full affirmation of Huakang Pharmaceutical's technical strength and R&D level. It is conducive to reducing the corporate tax burden and will have a positive effect on the business development of Huakang Pharmaceutical.
诚意药业(603811.SH)：控股子公司通过高新技术企业认定
Chengyi Pharmaceutical (603811.SH): The holding subsidiary passed the high-tech enterprise certification
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.